Take­da earns win for its TKI in­hibitor in tiny lung can­cer group — but GI side ef­fects could be an ear­ly red flag

Japan­ese drug­mak­er Take­da has made a big push in re­cent years to build a hand in on­col­o­gy, par­tic­u­lar­ly in the next-gen can­cer space. One of those can­di­dates, ty­ro­sine ki­nase in­hibitor (TKI) mobo­cer­tinib, re­cent­ly earned the FDA’s in­ter­est in a small sec­tion of un­treat­ed lung can­cer pa­tients, but will se­vere GI side ef­fects be a road­block?

Take­da’s oral mobo­cer­tinib post­ed clin­i­cal­ly sig­nif­i­cant ob­jec­tive re­sponse rates in a Phase I/II adap­tive tri­al drug­ging metasta­t­ic non-small cell lung can­cer pa­tients with EGFR ex­on 20 gene mu­ta­tions who had pre­vi­ous­ly un­der­gone plat­inum-based chemother­a­py, ac­cord­ing to da­ta pre­sent­ed Thurs­day at the vir­tu­al World Con­fer­ence on Lung Can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.